Dr. Daniel Fisher on ECT | Psych Central

Dr. Daniel Fisher presented to the U.S. Food and Drug Administration Neurological Devices Panel examining the reclassification of electroconvulsive therapy (ECT) devices on January 27, 2011. These are his remarks as published in the public record of the meeting. I represent a national mental health consumer organization, to answer an earlier question, the National Coalition for Mental Health Recovery, which represents millions of mental health consumers. I do not have any financial relationship with the manufacturers of ECT devices. I base my testimony on my practice as a board certified psychiatrist, my neurochemical research at National Institute of Mental Health, and my 19 years of directing a federally funded technical assistance center, the National Empowerment Center. I’m appalled that the FDA is considering downgrading ECT devices from Class III to Class II, the same classification as a wheelchair. In my expert opinion, and that of a recent review of ECT literature by Drs. Reed

Source: Dr. Daniel Fisher on ECT | Psych Central

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s